NASDAQ OMX

Novavax Reports First Quarter 2018 Financial Results

Dela

GAITHERSBURG, Md., May 09, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2018.

First Quarter and Subsequent Achievements:

RSV F Vaccine

  • In May 2018, Novavax reached enrollment of approximately 4,600 pregnant women in its Prepare(TM) Phase 3 clinical trial of its RSV F Vaccine for infants via maternal immunization. This milestone enables Novavax to initiate a prespecified interim efficacy analysis after approximately six months of follow-up of the last infant born to the approximately 4,600 women enrolled (including 3,000 actively vaccinated women). Completion of this analysis is expected in the first quarter of 2019. Since 2015, the Prepare trial is supported by an $89 million grant from the Bill & Melinda Gates Foundation (BMGF).
     
  • In April 2018, Novavax presented at the World Vaccine Congress on the status of its Phase 3 clinical trial of its RSV F Vaccine.

NanoFlu(TM)

  • In April 2018, Novavax presented clinical data at the World Vaccine Congress from the Phase 1/2 clinical trial in older adults comparing trivalent formulations of NanoFlu to the market-leading licensed egg-based, high-dose influenza vaccine for older adults.
     
  • In February 2018, Novavax reported positive top-line results from its Phase 1/2 clinical trial of its trivalent NanoFlu.

Corporate

  • In April 2018, Novavax completed an underwritten public offering of approximately 34.8 million shares of its common stock, including 4.5 million shares pursuant to the underwriters' option to purchase additional shares. The shares resulted in net proceeds of $54 million.
     
  • Effective on March 14, 2018, John J. Trizzino, former Senior Vice President, Commercial Operations since 2014, was promoted to Senior Vice President, Chief Business Officer and Chief Financial Officer.

Anticipated Events:

  • Initiation of the Phase 2 clinical trial of quadrivalent formulations of NanoFlu scheduled to begin in the third quarter of 2018.
     
  • Top-line data from the Phase 2 NanoFlu trial and End of Phase 2 meeting with the FDA expected in the first quarter of 2019.
     
  • Results of the Prepare Phase 3 interim efficacy analysis for our RSV F Vaccine expected in the first quarter of 2019.  

Summary

"We had an extremely productive first quarter, including making important advances in our two lead clinical vaccine programs. We are pleased to have reached the enrollment target for our Prepare Phase 3 RSV F Vaccine trial, which clears the path for following these most recent participants and their babies, and subsequently announcing top-line results of our planned interim efficacy analysis in the first quarter of 2019," said Stanley C. Erck, President and CEO of Novavax, Inc. "We also continue to make significant progress on NanoFlu and plan to initiate a Phase 2 clinical trial in the third quarter of 2018."

Financial Results for the First Quarter Ended March 31, 2018

Novavax reported a net loss of $46.4 million, or $0.14 per share, for the first quarter of 2018, compared to a net loss of $43.9 million, or $0.16 per share, for the first quarter of 2017.

Novavax revenue in the first quarter of 2018 was $9.7 million, compared to $5.7 million in the same period in 2017. This 70% increase was driven by higher revenue recorded under the BMGF grant corresponding to the increased enrollment in the Prepare trial.

Research and development expenses increased 18% to $44.5 million in the first quarter of 2018, compared to $37.7 million for the same period in 2017. The increase was primarily due to increased development activities of the RSV F Vaccine for infants via maternal immunization.

Interest income (expense), net for the first quarter of 2018 was ($2.9) million, compared to ($3.0) million for the same period of 2017.

As of March 31, 2018, Novavax had $164.2 million in cash, cash equivalents, marketable securities and restricted cash, compared to $186.4 million as of December 31, 2017. Net cash used in operating activities for the first quarter of 2018 was $66.1 million, compared to $44.5 million for same period in 2017. The increase in cash usage was primarily due to approximately $16 million of one-time payments, as well as the adoption of a new accounting standard that requires restricted cash to be included in the beginning and ending balances on the statements of cash flows, thus increasing Novavax' cash usage in the first quarter of 2018 and 2017 by approximately $9 million and $6 million, respectively. We expect our cash used in operating activities to significantly decrease for the subsequent quarters of 2018 as compared to the first quarter of 2018.

Conference Call

Novavax management will host its quarterly conference call today at 4:30 p.m. ET. The dial-in number for the conference call is (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 3687883. A replay of the conference call will be available starting at 7:30 p.m. ET on May 9, 2018 until 7:30 p.m. ET on May 16, 2018. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use passcode 3687883.

A webcast of the conference call can also be accessed via a link on the home page of the Novavax website at www.novavax.com or through the "Investor Info"/"Events" tab on the Novavax website. A replay of the webcast will be available on the Novavax website until August 9, 2018.

About RSV

RSV is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively.1 In the U.S., RSV is the leading cause of hospitalization of infants.2 Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common.3 Currently, there is no approved RSV vaccine available.

About RSV F Vaccine for Infants via Maternal Immunization

Novavax is developing a vaccine that targets the fusion protein, or F protein, of the RSV virus. The F protein has highly conserved amino acid sequences, called antigenic sites, which are the target of neutralizing antibodies and are believed to be ideal vaccine targets. Novavax' genetically engineered novel F protein antigen exposes a range of these antigenic sites, and can evoke immune responses to them in human vaccine recipients. In a previous Phase 2 clinical trial of the RSV F Vaccine, which assessed the transplacental transfer of maternal antibodies induced by the vaccine, immunized women demonstrated meaningful fold rises in anti-F IgG, palivizumab-competing antibodies and microneutralization titers. In addition, infants' antibody levels at delivery averaged 90-100% of the mothers' levels, indicating efficient transplacental transfer of antibodies from mother to infant.

About Influenza

Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies in humans. An estimated one million deaths each year are attributed to influenza.4 Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in 2015 to $5.3 billion by 2025.5

About NanoFlu(TM)

NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax' patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax' most advanced clinical programs and are at the forefront of Novavax' efforts to improve global health. For more information, please visit www.novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

1 https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv

2 Leader S. Pediatr Infect Dis J. 2002 Jul;21(7):629-32

3 PLOS. "How immunity to respiratory syncytial virus develops in childhood, deteriorates in adults." ScienceDaily. 21 April 2016. https://www.sciencedaily.com/releases/2016/04/160421145747.htm

4 Resolution of the World Health Assembly (2003) WHA56.19.28

5 Influenza Vaccines Forecasts. Datamonitor (2013)

 
 
NOVAVAX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
(unaudited)
                   
          Three Months Ended
          March 31,
                2018       2017  
                   
Revenue         $      9,653     $   5,680  
                   
Expenses:              
  Research and development           44,514       37,654  
  General and administrative           8,652       8,852  
    Total expenses           53,166       46,506  
Loss from operations           (43,513 )     (40,826 )
Interest income (expense), net           (2,872 )     (3,039 )
Other income (expense)           33       11  
Net loss         $      (46,352 )   $   (43,854 )
                   
Basic and diluted net loss per share         $      (0.14 )   $   (0.16 )
Basic and diluted weighted average              
  number of common shares outstanding           336,972       274,178  
                   

 

 
SELECTED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
 
  March 31,  
2018
  December 31,
2017
  (unaudited)    
Cash and cash equivalents $   113,402     $   106,307  
Marketable securities     30,358         50,996  
Total restricted cash     20,439         29,124  
Total current assets     181,034         203,311  
Working capital     136,130         129,636  
Total assets     276,067         302,493  
Notes payable     318,119         317,763  
Total stockholders' deficit     (99,369 )       (101,732 )
               
               

Contact:         

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Elite Capital & Co. Limited upgrades its quality management system to ISO 9001:201522.5.2018 12:00Pressmeddelande

LONDON, May 22, 2018 (GLOBE NEWSWIRE) -- The Public Relations Department of Elite Capital & Co. Limited has announced that it has upgraded its Quality Management System from ISO 9001:2008 to ISO 9001:2015, prompted by its keen desire to provide its customers with the best services and assert its steady strides in the global finance market under the leadership of a management team that stands on a solid ground. On this occasion Elite Capital's chairman, Kuwaiti businessman, Dr. Faisal Khazaal expressed his deepest thanks and congratulations to the Company's president, Mr. George Matharu and the members of the Board of Directors and all the members of the company's executive management for their exceptional efforts toward raising customer service to the highest levels. Elite Capital & Co. Limited is a private limited company that provides project-related services, including management, consultancy and funding, particularly for large infrastructure and commercial projects. Elite Capital &

LeoVegas avslutar samarbetet med Frank Andersson22.5.2018 11:31Pressmeddelande

LeoVegas väljer att avsluta samarbetet med varumärkesambassadören Frank Andersson. Samarbetet avslutas då LeoVegas nyligen lanserat ett nytt kommunikationskoncept som bygger på flera varumärkesambassadörer. "Vi tackar för de år som Frank hjälpt till att profilera LeoVegas i Sverige. Han har varit en bidragande orsak till LeoVegas starka tillväxt på den svenska marknaden. LeoVegas har gått in i en ny fas med fler varumärken och en större bredd med fler produktkategorier. Efter ett långvarigt och framgångsrikt samarbete med Frank är det nu dags att ta nästa steg". säger Gustaf Hagman, CEO LeoVegas. " Jag har koncept och idéer på att utveckla egna spel och vill satsa mer på det, så det blir nästa steg för mig. Det har varit roliga år med LeoVegas och jag vill tacka LeoVegas för att dom har trott på mig och vi har haft riktigt kul tillsammans". säger Frank Andersson. För ytterligare information, vänligen kontakta: Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, gustaf.hagman@leovegas.com P

LeoVegas concludes partnership with Frank Andersson22.5.2018 11:31Pressmeddelande

LeoVegas has decided to conclude its partnership with brand ambassador Frank Andersson. The partnership is being concluded in connection with the recent launch by LeoVegas of a new communication concept that is based on several brand ambassadors. "We thank Frank for the years he has helped profile LeoVegas in Sweden. He has been a contributing factor behind LeoVegas' strong growth in the Swedish market. LeoVegas has entered a new phase with several brands and greater breadth with more product categories. After a long and successful cooperation with Frank, it is now time to take the next step," comments Gustaf Hagman, CEO of LeoVegas. "I have concepts and ideas for developing my own games and want to focus more on this, so that will be the next step for me," says Frank Andersson. "I had some great years with LeoVegas and want to thank LeoVegas for believing in me. We had a great time working together!" For further information, please contact : Gustaf Hagman, Group CEO: +46 (0) 8 410 367

Gunvor Group, Oceangold Tankers and Maas Capital Form ClearOcean Tankers JV22.5.2018 11:30Pressmeddelande

Gunvor SA / Gunvor Group, Oceangold Tankers and Maas Capital Form ClearOcean Tankers JV . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. "ClearOcean Tankers" has ordered 6 eco-friendly, scrubber-ready tankers NICOSIA, Cyprus, May 22, 2018 (GLOBE NEWSWIRE) -- Gunvor Group, one of the largest physical energy trading companies in the world, has entered into a joint venture with Oceangold Tankers and Maas Capital to form ClearOcean Tankers, a new ship holding company. The three partners hold an equal share in ClearOcean Tankers, which has been incorporated in Cyprus. ClearOcean Tankers has entered into shipbuilding contracts with STX Offshore & Shipbuilding Co. for four MR2 product tankers, and with Daehan Shipbuilding Co for two LR2 product tankers. All six of the contracted vessels will be delivered during the first half of 2019, and will be eco-friendly and scrubber-ready, in view of the International Marit

Doc re. GE Files Form 8-K22.5.2018 08:00Pressmeddelande

FAIRFIELD,Conn., May 22, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-K May 21, 2018 On May 21, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, p

Introducing AbacusNext International, Technology Solutions Provider to the UK, Europe, and Beyond22.5.2018 07:00Pressmeddelande

US Based AbacusNext incorporates AbacusNext International in Edinburgh, the new international headquarters of their globally expanding TaaS platform EDINBURGH, United Kingdom, May 22, 2018 (GLOBE NEWSWIRE) -- AbacusNext®, the largest Technology-as-a-Service (TaaS) provider for the professional services sector, today announced that two-time Queen's Award Winner HotDocs Ltd-recently integrated into the AbacusNext family of products-will be reorganized under the newly incorporated AbacusNext International Ltd. The HotDocs brand and product suite will remain as a subsidiary within AbacusNext International's expanded slate of products and services for business. From its new headquarters in Edinburgh, Scotland, AbacusNext International will bring the fully-managed private cloud solutions and business technology services they pioneered in the North American market to the UK and Europe for the first time. The centerpiece of AbacusNext International's TaaS platform is Abacus Private Cloud, offe

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum